Skip to content

Orenitram® (treprostinil)

Behind you all the way.

Our team will work with your patients to identify any potential obstacles to access and affordability and how we may be able to assist with overcoming them.

Start a referral.

Referral form

To start your patients on Orenitram® (treprostinil) and help them enroll in United Therapeutics Cares™, work with them to complete the referral form and fax it to 1-800-380-5294.

Download referral form

Electronic prescription

If you prefer, you can also prescribe electronically with iAssist. To get started, follow these simple steps:

  1. Follow the 3-step registration process
  2. Set up users for the account
  3. Go to the Start Now section on your dashboard
  4. Search for Orenitram®
ePrescribe
A woman smiles and laughs

Step 1

Education & Expectations

Upon enrollment, the Patient Navigator  will introduce your patient to our program offerings, and establish an appropriate check-in schedule. They will be there to help answer questions your patient may have regarding the safe and effective use of their United Therapeutics treatment and review what to expect in their treatment journey.

Step 2

Coverage & Reimbursement

United Therapeutics Cares will educate your office on the benefits investigation process, including the requirements for prior authorizations and appeals. For patients, we’ll walk through the ins and outs of the insurance landscape and where their specific plan fits in.

Benefits investigations

Our Patient Navigators will initiate the benefits investigation process and educate your patients on navigating access and affordability challenges that may arise.

Benefits investigations

Our Patient Navigators will initiate the benefits investigation process and educate your patients on navigating access and affordability challenges that may arise.

Prior authorizations

Certain medications may require prior authorization. These requirements vary by health plan or pharmacy benefit manager (PBM), but we’ll offer materials that can help educate you through the submission process and keep you informed of your patient’s status.

Prior authorizations

Certain medications may require prior authorization. These requirements vary by health plan or pharmacy benefit manager (PBM), but we’ll offer materials that can help educate you through the submission process and keep you informed of your patient’s status.

Denials and appeals

If your patient’s coverage is denied, we can provide education on next steps regarding the appeal process and the information needed by the insurer.

Denials and appeals

If your patient’s coverage is denied, we can provide education on next steps regarding the appeal process and the information needed by the insurer.

Step 3

Cost & Savings

If a patient is in need of financial assistance to cover the remaining out-of-pocket costs of their prescription, their Patient Navigator can connect them with one of our Access & Affordability Specialists  who can provide information on options that may be available to them.

Co-pay assistance

If your patient has a commercial insurance plan, our co-pay assistance program can help cover out-of-pocket expenses. Eligible patients pay as little as a $0 co-pay per month for Orenitram®. The United Therapeutics Cares Co-Pay Assistance Program will pay the difference up to a monthly maximum program benefit.*

Terms & Conditions *Patients must meet certain eligibility criteria to qualify for assistance. Patients receiving reimbursement under Medicare, Medicaid, VA, DoD (TRICARE), Indian Health Services, or similar federal or state programs, may not be eligible for some assistance. Some portion of this patient assistance may be administered by third-party patient assistance organizations. The Program is subject to additional state law restrictions. Patients residing in select states may not be eligible for the Program.

Co-pay assistance

If your patient has a commercial insurance plan, our co-pay assistance program can help cover out-of-pocket expenses. Eligible patients pay as little as a $0 co-pay per month for Orenitram®. The United Therapeutics Cares Co-Pay Assistance Program will pay the difference up to a monthly maximum program benefit.*

Terms & Conditions *Patients must meet certain eligibility criteria to qualify for assistance. Patients receiving reimbursement under Medicare, Medicaid, VA, DoD (TRICARE), Indian Health Services, or similar federal or state programs, may not be eligible for some assistance. Some portion of this patient assistance may be administered by third-party patient assistance organizations. The Program is subject to additional state law restrictions. Patients residing in select states may not be eligible for the Program.

Patient Assistance Program (PAP)

If patients are uninsured or underinsured, they may meet the eligibility requirements for our Patient Assistance Program (PAP). For more eligibility information, you can contact their Patient Navigator.

Patient Assistance Program (PAP)

If patients are uninsured or underinsured, they may meet the eligibility requirements for our Patient Assistance Program (PAP). For more eligibility information, you can contact their Patient Navigator.

Additional financial resources

Our commitment to your patients’ care goes beyond our program’s support and education. If their situation requires more assistance, there may be additional options for your patient to explore.

Additional financial resources

Our commitment to your patients’ care goes beyond our program’s support and education. If their situation requires more assistance, there may be additional options for your patient to explore.

two people enjoy a laugh on the porch

Step 4

Prescription Coordination

Once all benefits have been verified and financial assistance options are reviewed, the Patient Navigator will walk your patient through getting set up with their Specialty Pharmacy. The Specialty Pharmacy will work directly with your patient to coordinate any final prescription details and confirm shipping preferences.

This is how Specialty Pharmacies work:

  1. Your Specialty Pharmacy will conduct a review of your patient’s insurance benefits.
  2. Your Specialty Pharmacy will confirm your patient’s medication coverage.
  3. Your Specialty Pharmacy will call your patient to review co-payment and insurance coverage.
  4. Shipments will be scheduled for delivery where it’s most convenient for your patient.

Our Orenitram® (treprostinil) Specialty Pharmacy network and Specialty Distributor

Accredo

CVS Specialty

CuraScript SD

Step 5

Treatment Support

After working with your patients to determine how often it’s helpful for us to be in touch, the Patient Navigator will set up regular check-ins. This is an opportunity for United Therapeutics Cares to share important information about your patient’s therapy journey and connect them with additional education or resources as needed.

A doctor speaks with a patient while working on a laptop

Education specialists

Our Patient Education Specialists  are available to work with your patients one-on-one to provide education on their condition and answer questions about the safe and effective use of their United Therapeutics therapy.

Get to know them
A woman sits outdoors with friends

Support organizations

There are organizations that understand your patient’s condition and have firsthand experience to help them through their treatment journey.

Explore the community

Looking for additional resources?

Patients deserve ready access to education and support. That’s why we offer a suite of resources, including treatment-specific brochures, to offer education anytime your patient may need it.

See all resources

For you:

  • Orenitram sample statement of medical necessity

  • Orenitram sample appeal letter

For your patients:

  • Guide when considering Orenitram

  • What to expect with Orenitram

  • Starting the Orenitram Titration Kit

  • Orenitram: Guide to getting started

  • Orenitram daily treatment journal/tracker

  • Managing titration side effects with Orenitram

  • Understanding dosing with Orenitram

  • How our Orenitram Titration Kit works

A woman reads on an electronic device

Browse our full resource library.

Explore resources
Expand

IMPORTANT SAFETY INFORMATION FOR ORENITRAM

CONTRAINDICATIONS

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

WARNINGS AND PRECAUTIONS

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

ADVERSE REACTIONS

  • In the 12-week, placebo-controlled, monotherapy study, and an event-driven placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

IMPORTANT SAFETY INFORMATION FOR ORENITRAM

CONTRAINDICATIONS

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

WARNINGS AND PRECAUTIONS

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

ADVERSE REACTIONS

  • In the 12-week, placebo-controlled, monotherapy study, and an event-driven placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

DRUG INTERACTIONS

  • Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

SPECIFIC POPULATIONS

  • Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
  • It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
  • Safety and effectiveness of Orenitram in pediatric patients have not been established.
  • Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
  • There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

INDICATION

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

Please see Full Prescribing Information and Patient Information at www.orenitram.com or call 1-877-UNITHER (1-877-864-8437).

OREISIhcpOCT19